Pyrilutamide promised a cleaner topical antiandrogen than RU58841. The Phase III data and real-world logs tell a more nuanced story about where it actually fits in a hair stack.
Pyrilutamide (KX-826) showed up in the hair-retention conversation as the "safer RU" — a topical androgen receptor antagonist with the systemic-safety pitch that finasteride never quite gets to make. Then the Kintor Phase III readouts in 2023-2024 came in soft, the forums turned, and the compound went from heir-apparent to question mark almost overnight. The reality is more interesting than either camp claims, and for a specific subset of users — particularly anyone who has burned through fin, dut, minoxidil, and is wary of RU58841's reputation — pyrilutamide still earns a slot. The question is where, at what dose, and stacked with what.
Pyrilutamide is a non-steroidal AR antagonist designed for topical scalp application, with the explicit goal of being cleared locally and avoiding the systemic androgen-blockade profile that gives RU58841 its sketchy reputation. Mechanism is straightforward: it competes with DHT at the follicular androgen receptor. It does not lower serum DHT (that is the fin/dut lane), and it does not stimulate the follicle directly (that is the minoxidil lane). It occupies the receptor so circulating DHT cannot dock.
Three practical implications fall out of that mechanism:
The blunt reading: Kintor's Phase III in male AGA missed its primary endpoint on TAHC (target area hair count) versus vehicle by the margin investors wanted, even though the active arm did improve on baseline. The Phase II data had been more flattering. That gap is the source of most of the current skepticism.
What the trial result does not establish:
So the honest summary is: weaker monotherapy signal than the hype suggested, mechanism intact, optimal protocol unsettled.
Pyrilutamide is most defensible as a third or fourth agent, not a fin/dut replacement. The slots that make sense:
| Stack position | Rationale |
|---|---|
| Add-on to oral fin/dut + minoxidil plateau | Adds receptor-level blockade to supply-level blockade. Cheapest marginal gain. |
| RU58841 substitution for sides-sensitive users | Lower reported systemic-feeling sides in community logs; cleaner pharmacokinetic story on paper. |
| Topical AR layer for AAS users who refuse oral 5-ARIs | Local blockade without touching systemic DHT — relevant when libido, mood, or fertility on cycle matter. |
| Post-microneedling absorption window | 24h after a 1.0-1.5mm session, with minoxidil or a retinoid-primed scalp. |
What does not make sense: dropping finasteride for pyrilutamide monotherapy because the topical "feels safer." The Phase III data does not support that swap. Users who genuinely cannot tolerate oral 5-ARIs are better served by topical finasteride plus pyrilutamide than by pyrilutamide alone.
Community protocols cluster around:
Irritation is the most common complaint, and it is dose- and vehicle-driven. Dropping to once daily or diluting with a bland carrier resolves most cases. Scalp itch reduction is a recurring positive note in user logs, mirroring RU experiences:
Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline. — tressless community thread
The single most common mistake is evaluating an antiandrogen on the wrong endpoint. Pyrilutamide, like fin and RU, is primarily a retention tool. The hierarchy of expected outcomes:
If shedding has not stabilized by month 4 on a properly dosed protocol with fin or dut underneath, pyrilutamide is unlikely to be the missing piece and the stack should pivot — usually to RU58841, oral minoxidil titration, or a microneedling cadence audit (1.0-1.5mm, weekly to biweekly, not daily 0.5mm theatre).
Pyrilutamide remains expensive relative to RU58841 on a per-month basis through research-chemical channels, and supply quality is uneven. Pre-mixed solutions vary in concentration accuracy; raw powder plus a known vehicle is generally the more controllable route for users who already keep a scale and PG/ethanol on hand. Until a major regulator approves it, third-party COAs are the only quality signal that matters — vendor marketing copy is not.
Pyrilutamide is not the fin-killer the early hype implied, and the Phase III miss is real. It is also not a dead compound. As an add-on to a fin-or-dut + minoxidil base, as an RU58841 substitute for users who want a cleaner systemic profile, or as the topical AR layer for AAS users protecting libido and fertility, it earns its place. The users who get burned are the ones running it as monotherapy and expecting fin-tier retention. Run it as a third agent, evaluate on shed and miniaturization at months 3 and 6, and treat cosmetic regrowth as upside rather than the entry ticket.
Powered by BTST